Back to Search
Start Over
Possibilities of using coenzyme Q10 for the treatment of diseases associated with mitochondrial dysfunction and chronic inflammation
- Source :
- Фармакоэкономика, Vol 16, Iss 3, Pp 466-480 (2023)
- Publication Year :
- 2023
- Publisher :
- IRBIS LLC, 2023.
-
Abstract
- Background. The enzymatic cofactor coenzyme Q10 (CoQ10) is involved in the synthesis of adenosine triphosphate in mitochondria. The CoQ10 biosynthesis declines when using statin drugs.Objective: systematization of the impact of coenzyme Q10 on chronic, sluggish systemic inflammation leading to the development of atherosclerosis, liver and pancreas pathologies, and neurodegeneration.Material and methods. Systematic computer analysis of 16,788 publications on CoQ10 found by the query “coenzyme Q10 OR ubiquinone” in PubMed/MEDLINE database of biomedical publications was carried out. Current methods of topological and metric data analysis developed at the scientific school of Academician of the Russian Academy of Sciences Yu.I. Zhuravlev were used.Results. CoQ10 is involved in the regulation of inflammation and exhibits lipid-lowering, hepatoprotective, nephroprotective, anti-asthenic, cardioprotective, and neuroprotective effects. CoQ10 favorably affects carbohydrate metabolism and a wide range of neurological diseases.Conclusion. CoQ10 supplementation improves glycemic control in insulin resistance, kidney function, and is useful in the treatment of migraine and neurodegenerative pathologies (Parkinson’s disease, etc.).
Details
- Language :
- Russian
- ISSN :
- 20704909 and 20704933
- Volume :
- 16
- Issue :
- 3
- Database :
- Directory of Open Access Journals
- Journal :
- Фармакоэкономика
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.62644e24712b4b74bd83a87c254149c1
- Document Type :
- article
- Full Text :
- https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.187